699011-59-1

Basic information

• Product Name: 4-(1-methylhydrazino)-5-cyano-7-[(2,3,5-tri-O-benzoyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine
• Synonyms: 4-(1-methylhydrazino)-5-cyano-7-[(2,3,5-tri-O-benzoyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine
• CAS NO: 699011-59-1
• Molecular Weight: 632.632
• Mol File: 699011-59-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(1-methylhydrazino)-5-cyano-7-[(2,3,5-tri-O-benzoyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-methylhydrazino)-5-cyano-7-[(2,3,5-tri-O-benzoyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine(699011-59-1)
• EPA Substance Registry System: 4-(1-methylhydrazino)-5-cyano-7-[(2,3,5-tri-O-benzoyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine(699011-59-1)

Safety Data

• Hazardous Substances Data: 699011-59-1(Hazardous Substances Data)

Upstream product

• 60-34-4 methylhydrazine 
• 123148-78-7 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine 
• 480439-89-2 4-chloro-5-iodo-7-[(2,3,5-tri-O-benzoyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 6974-32-9 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
• 19393-83-0 4-amino-6-bromo-5-cyanopyrrolo[2,3-d]pyrimidine 
• 24391-40-0 6-Bromo-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 
• 24391-39-7 6-bromo-4-chloro-5-cyanopyrrolo[2,3-d]pyrimidin-4-one 
• 699011-57-9 6-bromo-4-chloro-5-cyano-7-[2,3,5-tri-O-benzoyl-β-D-ribofuranosyl]pyrrolo[2,3-d]pyrimidine 
• 699011-58-0 6-bromo-5-cyano-4-(1-methylhydrazino)-7-[2,3,5-tri-O-benzoyl-β-D-ribofuranosyl]pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 35943-35-2 triciribine 

Relevant articles and documents

Expedient total synthesis of triciribine and its prodrugs

Triciribine (TCN, 1) and its monophosphate (TCNP, 2) are ricyclic nucleotide derivatives that have potential antineoplastic activity. Triciribine inhibits the phosphorylation, activation, and signaling of Akt-1, -2, and -3, which may result in the inhibition of Akt-expressing tumor cell proliferation. Both TCN and TCNP have very low bioavailability, and the development of both drugs as intravenous (IV) treatments was halted because of the toxicity induced by the high doses needed for their use as general cytotoxic agents. This publication describes an expedient and straightforward total synthesis of amino acid prodrugs (3, 4) of TCN and TCNP. In our study, both the prodrugs significant improved the plasma exposure of the parent drugs and the prodrugs.Copyright TSRL Inc.